Please assess the completion status of the following clinical trial:

Trial Title: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive adults \> or = 19 years of age~* receiving stable therapy including one or two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in conjunction with a once-daily protease inhibitor (PI) (atazanavir, lopinavir or darunavir) and twice daily raltegravir or once daily dolutegravir~* Virologic suppression for \>6 months, defined as plasma viral load (VL) consistently \< 200 copies/mL with no evidence of prior virologic rebound (VL \> 1000 copies/mL) on the NRTI/PI/Raltegravir regimen, AND VL \< 50 copies/mL at time of study screening~* Estimated glomerular filtration rate (eGFR) \> o r= 70mL/min at screening~Exclusion Criteria:~* Prior documented viral rebound \> 1000 copies/mL on any raltegravir-containing regimen~* Evidence of resistance mutations compromising raltegravir or elvitegravir activity on prior genotypes.~* Evidence of clinically significant resistance to tenofovir on any previous genotype tests: K65R mutation, or 3 or more thymidine-analogue associated mutations (TAMS) compromising tenofovir activity~* Evidence of resistance mutations significantly compromising darunavir activity on any previous genotypic tests~* Current use of any nonnucleoside reverse transcriptase inhibitor (NNRTI)~* Pregnancy or breast-feeding~* Contraindications to tenofovir/FTC, elvitegravir, or cobicistat (e.g. previous significant toxicity, intolerance or drug interactions

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment simplification (Type: EXPERIMENTAL): Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food

Based on this trial design, predict the completion outcome and termination type (if applicable).